Market Access | Getting therapies in patients' hands

News

Bayer pledges $2.2bn to US manufacturing facility

Bayer has joined the ranks of pharma groups planning major facility investments in the US, with a $2.2bn plan for a new production unit in Ohio.

News

NICE backs Sobi's Tryngolza for rare disease FCS

Patients in England and Wales with familial chylomicronaemia syndrome will soon have a new treatment option, as NICE backs Sobi's Tryngolza.

News

GLOBE model finalised, with narrowed scope and fewer savings

CMS has finalised a new drug pricing policy for Medicare that has drawn sharp criticism from the pharma industry.

News

PhRMA hires ex-House Majority Leader Eric Cantor as its CEO

Former Republican lawmaker Eric Cantor has been named as the new CEO of US pharma group PhRMA, replacing long-serving Stephen Ubl.

News

FDA clears first drug for MCT8 deficiency

Sweden's Egetis has won approval in the US for the first-ever treatment for people living with the ultra-rare genetic disease MCT8 deficiency.

News

Orchard's gene therapy for MLD finally gets US approval

The FDA has cleared its first gene therapy for kids with metachromatic leukodystrophy (MLD), a rare genetic disorder of the brain and nervous centre.

News

CAR-T earlier use backing in multiple myeloma

CAR-Ts set to move earlier in multiple myeloma therapy

FDA advisors have said that two BCMA-targeted CAR-T therapies can be used earlier in the treatment pathway for multiple myeloma, setting up FDA approvals for use in a broa

News

Madrigal Pharma is first over the MASH finish line

Madrigal Pharma has become the first drugmaker to claim FDA approval for a drug to treat metabolic dysfunction-associated steatohepatitis (MASH), an elusive target that ha

News

Bayer pledges $2.2bn to US manufacturing facility

Bayer has joined the ranks of pharma groups planning major facility investments in the US, with a $2.2bn plan for a new production unit in Ohio.

News

NICE backs Sobi's Tryngolza for rare disease FCS

Patients in England and Wales with familial chylomicronaemia syndrome will soon have a new treatment option, as NICE backs Sobi's Tryngolza.

Press Releases

Partner Content

Xcovery Partners with EVERSANA to Commercialize Lung Cancer ...

EVERSANA will provide comprehensive end-to-end commercialization services for Xcovery

Market Access

VuuAI and Amiculum partner to transform content engagement i...

Amiculum, a global health communications agency, has entered into an exciting strategic collaboration with VuuAI, a GenAI-driven content production automation plat

Views & Analysis

Market Access

Chinese flag atop pills on black background

Is the next generation of Chinese biotech ready to go global...

Will Chinese biotechs continue to transfer most ex-China rights, or retain their strongest assets and compete internationally themselves?

Market Access

Two business hands outstretched, one weighing cash, the other drugs, for balance

What the revised 340B rebate pilot programme means for pharm...

While the scope of the revised pilot is limited, it may be a harbinger for a broader policy shift.

Deep Dive

Market Access

Can direct-to-employer models close the GLP-1 obesity care g...

Market Access

The expanding role of early-phase trials in modern drug deve...

Market Access

Market Access 2026

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Webinars

IQVIA Webinar on Innovative Medicines Fund

Sponsored

Innovative Medicines Fund and the opportunity for ICSs to mo...

In June, NHSE and NICE published details on the Innovative Medicines Fund, which will help improve patient access to cutting-edge medicines, with a particular focus on rare diseases, and en

Webinars

Sponsored

Medical Informatics and Rare Disease: a bridge between two w...

With more than 6,000 different diseases comprising the rare disease (RD) landscape, connecting patients and practitioners with the expertise needed to achieve th

Webinars

Sponsored

ICSs - an opportunity to improve Patient & Market Access at ...

With the new Health and Care Bill edging ever closer to receiving Royal Assent, life sciences companies in the UK are preparing to navigate the most significant piece of NHS legislation in

Podcasts

Market Access

pharmaphorum podcast Episode 275, Giancarlo Benelli, BeOne Medicines

Sponsored

Europe for life sciences and for patients, with BeOne Medici...

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Giancarlo Benelli, SVP & Head of Europe at BeOne Medicines.

Market Access

pharmaphorum podcast Episode 270, Alice Valder Curran, Hogan Lovells

Policy in Focus: What’s new with CMS drug price negotiation,...

Hogan Lovells partner Alice Valder Curran returned to elucidate some of the finer points of the latest communication from CMS.

Market Access

Policy in Focus: Unpacking GLOBE, GUARD, and TrumpRx with Al...

Unpack the impact of Most-Favoured Nations in GLOBE and GUARD pricing models, and TrumpRx, with Alice Valder Curran's clear policy overview.

Video

Patients

Interview with Matt Wadyka at Reuters Pharma USA 2026

Making direct-to-patient work, with Matt Wadyka

Matt Wadyka, chief client strategy officer at Inizio Medical, spoke to pharmaphorum about the ins and outs of direct-to-patient programmes in pharma.

Market Access

Interview with Marjorie Sidhoum at BIO Europe 2026

BIO-Europe Spring 2026: In conversation with Marjorie Sidhou...

Marjorie Sidhoum, vice president of business development & corporate communication at Kainova Therapeutics, discusses their immuno-oncology pipeline.

Market Access

Consolidating data strategy for global success: Insights fro...

At Frontiers Health 2025, Drew McCormick, Head of Data and Analytics at EVERSANA, emphasised a critical truth: data strategy is launch strategy.

White Papers

Spotlight on

Life Sciences Industry Report Part 1 Download

Life Sciences Industry Report 2025

In pharmaphorum’s inaugural Life Sciences Industry Report 2025, delve into the trends that propelled the pharmaceutical industry along in 2024.

Market Access

Sponsored

Navigating Routes to Commercial Excellence in Cell and Gene ...

'Navigating Routes to Commercial Success in Cell and Gene Therapy', authored by Franjo Hanzl, VP, Business Development, Commercial at EVERSANA, Dr.

Debates & Insight

Sponsored

Pricing & Market Access Outlook 2015/2016 Edition

Pricing and market access (P&MA) are key issues for the pharma industry as healthcare budgets continue to tighten and the value of innovative drugs, particularly in areas of high unmet need

Event

Partner Content

5th Sustainability in Life Sciences Summit

Join the global sustainability community this November in Boston

Event

Media Partner

What's on the Agenda at the DIA-MHRA Global Summit

See which regulators and industry leaders are speaking in each DIA-MHRA Global Summit session.

Event

Media Partner

Who's Speaking at the DIA-MHRA Global Summit 2026?

See who's speaking when regulators and industry convene at the DIA-MHRA Global Summit

Market Access

Sponsored

Innovative contracting in Europe – a Trojan horse?

Overview

Market Access

Sponsored

Launch excellence in a disrupted world – challenges & opport...

Overview

Market Access

Sponsored

Orphan medicines launch excellence: sustaining launch succes...

Overview Launching orphan medicines excellently will become even more important over the next five years as more patients with rare diseases have pharmacotherapies available.

Partner Content

Event

Partner Content

5th Sustainability in Life Sciences Summit

Join the global sustainability community this November in Boston

Event

Media Partner

What's on the Agenda at the DIA-MHRA Global Summit

See which regulators and industry leaders are speaking in each DIA-MHRA Global Summit session.

Event

Media Partner

Who's Speaking at the DIA-MHRA Global Summit 2026?

See who's speaking when regulators and industry convene at the DIA-MHRA Global Summit

News

Press Releases

Views & Analysis

Editor's Picks

Deep Dive

Webinars

Podcasts

Video

White Papers

Event

Debates & Insight

Partner Content

Editor's Picks